risedronic acid has been researched along with Periodontitis in 6 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Periodontitis: Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to develop a chitosan-based risedronate/zinc-hydroxyapatite intrapocket dental film (CRZHDF) for applications in the treatment of alveolar bone loss in an animal model of periodontitis." | 7.88 | Effect of locally administered novel biodegradable chitosan based risedronate/zinc-hydroxyapatite intra-pocket dental film on alveolar bone density in rat model of periodontitis. ( Khajuria, DK; Razdan, R; Zahra, SF, 2018) |
| "The aim of this study was to develop a chitosan-based risedronate/zinc-hydroxyapatite intrapocket dental film (CRZHDF) for applications in the treatment of alveolar bone loss in an animal model of periodontitis." | 3.88 | Effect of locally administered novel biodegradable chitosan based risedronate/zinc-hydroxyapatite intra-pocket dental film on alveolar bone density in rat model of periodontitis. ( Khajuria, DK; Razdan, R; Zahra, SF, 2018) |
| "The present study was designed to evaluate the effects of risedronate, one of the most potent bisphosphonates, on alveolar bone resorption and angiogenesis in rats with experimental periodontitis to identify dose-response curves and treatment durations that can be therapeutic for periodontal therapy versus those associated with osteonecrosis of the jaws." | 1.35 | Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats. ( Ayas, B; Cetinkaya, BO; Gurgor, P; Keles, GC, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khajuria, DK | 1 |
| Zahra, SF | 1 |
| Razdan, R | 1 |
| Fernández Ayora, A | 1 |
| Herion, F | 1 |
| Rompen, E | 1 |
| Reginster, JY | 1 |
| Magremanne, M | 1 |
| Lambert, F | 1 |
| Cetinkaya, BO | 1 |
| Keles, GC | 1 |
| Ayas, B | 1 |
| Gurgor, P | 1 |
| Hasegawa, T | 1 |
| Ri, S | 1 |
| Umeda, M | 1 |
| Komatsubara, H | 1 |
| Kobayashi, M | 1 |
| Shigeta, T | 1 |
| Yoshitomi, I | 1 |
| Ikeda, H | 1 |
| Shibuya, Y | 1 |
| Asahina, I | 1 |
| Komori, T | 1 |
| Lane, N | 1 |
| Armitage, GC | 1 |
| Loomer, P | 1 |
| Hsieh, S | 1 |
| Majumdar, S | 1 |
| Wang, HY | 1 |
| Jeffcoat, M | 1 |
| Munoz, T | 1 |
| Shoji, K | 1 |
| Horiuchi, H | 1 |
| Shinoda, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of the Effects of Bisphosphonate on the Gingival Crevicular Fluid Levels of Sclerostin and the DKK-1 in Individuals With Postmenopausal Osteoporosis With Periodontal Changes[NCT04149405] | Phase 4 | 43 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Effect of Periodontal Therapy and Bisphosphonates on Gingival Crevicular Fluid Levels of Nuclear Factor- κb Ligand (RANKL) and Osteoprotegerin in Postmenopausal Osteoporosis: Results of a 12-Month Study[NCT02808988] | Phase 4 | 47 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
levels of dickkopf-related protein-1 in 12th month (NCT04149405)
Timeframe: 12 months
| Intervention | ng/ml (Mean) |
|---|---|
| Group A | 3440.67 |
| Group B | 3203.802 |
| Group C | 2490.553 |
| Group D | 4269.39 |
levels of dickkopf-related protein-1 in 6th month (NCT04149405)
Timeframe: 6 months
| Intervention | ng/ml (Mean) |
|---|---|
| Group A | 3358.265 |
| Group B | 1963.185 |
| Group C | 3263.665 |
| Group D | 4269.39 |
levels of sclerostin in 12th month (NCT04149405)
Timeframe: 12 month
| Intervention | ng/ml (Mean) |
|---|---|
| Group A | 1702.265 |
| Group B | 1347.330 |
| Group C | 1114.988 |
| Group D | 2131.87 |
levels of sclerostin in 6th month (NCT04149405)
Timeframe: 6 months
| Intervention | ng/ml (Mean) |
|---|---|
| Group A | 1389.177 |
| Group B | 1085.405 |
| Group C | 1596.585 |
| Group D | 2131.87 |
1 trial available for risedronic acid and Periodontitis
| Article | Year |
|---|---|
Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Chemotherapy, Adjuvant; Dental Scaling; Dipho | 2005 |
Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Chemotherapy, Adjuvant; Dental Scaling; Dipho | 2005 |
Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Chemotherapy, Adjuvant; Dental Scaling; Dipho | 2005 |
Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Chemotherapy, Adjuvant; Dental Scaling; Dipho | 2005 |
5 other studies available for risedronic acid and Periodontitis
| Article | Year |
|---|---|
Effect of locally administered novel biodegradable chitosan based risedronate/zinc-hydroxyapatite intra-pocket dental film on alveolar bone density in rat model of periodontitis.
Topics: Alveolar Bone Loss; Animals; Bone Density; Bone Density Conservation Agents; Chitosan; Drug Carriers | 2018 |
Dramatic osteonecrosis of the jaw associated with oral bisphosphonates, periodontitis, and dental implant removal.
Topics: Administration, Oral; Aged, 80 and over; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecro | 2015 |
Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats.
Topics: Alveolar Bone Loss; Alveolar Process; Animals; Blood Vessels; Bone Density; Bone Density Conservatio | 2008 |
The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Antibiotic Prophylaxis; Bisphosph | 2013 |
Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats.
Topics: Alveolar Bone Loss; Analysis of Variance; Animals; Bone Density; Calcium Channel Blockers; Cell Coun | 1995 |